Region Norrbotten

Futó vizsgálatok

• Toboroz

  A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)

  NCT06452277· 3. fázis· Forrás

• Fut, nem toboroz

  A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma

  NCT05827016· 3. fázis· Forrás

• Toboroz

  SACK

  2022-501600-10-00· 3. fázis· Forrás

• Fut, nem toboroz

  Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma

  NCT05409066· 3. fázis· Forrás

• Fut, nem toboroz

  Acalabrutinib and Rituximab in Elderly Patients With Untreated Mantle Cell Lymphoma

  NCT05214183· 2. fázis· Forrás

• Toboroz

  Concomitant HPV Vaccination and HPV Screening HPV Infection and Cervical Cancer in Sweden

  NCT04910802· 4. fázis· Forrás

• Fut, nem toboroz

  Ibrutinib Monotherapy Versus Fixed-duration Venetoclax Plus Obinutuzumab Versus Fixed-duration Ibrutinib Plus Venetoclax in Patients With Previously Untreated Chronic Lymphocytic Leukaemia (CLL)

  NCT04608318· 3. fázis· Forrás

• Toboroz

  A Randomized, Multicenter, Phase III Trial Comparing Treatment With R-mini-CHOP With R-mini-CHP + Polatuzumab Vedotin in Patients With Diffuse Large Cell B Cell Lymphoma

  NCT04332822· 3. fázis· Forrás

• Fut, nem toboroz

  HEAT-AML (Hydroxyurea-Enhanced Ara-C Treatment of Adult Acute Myeloid Leukaemia): A clinical study to assess whether addition of hydroxyurea to standard treatment against acute myeloid leukaemia (AML) is safe and efficacious

  2023-509019-97-00· 1/2. fázis· Forrás

• Lezárult

  Long-acting Low Dose Ropeginterferon for Chronic Myeloid Leukemia Treated With Bosutinib From Diagnosis

  NCT03831776· 2. fázis· Forrás

• Fut, nem toboroz

  ENRICH - Randomised, open label study of Rituximab/Ibrutinib vs Rituximab/Chemotherapy in older patients with untreated mantle cell lymphoma

  2024-514275-18-00· 2/3. fázis· Forrás

• Lezárult

  Ablative STEreotactic RadiOtherapy wIth Durvalumab (MEDI4736)

  NCT03446547· 2. fázis· Forrás

• Fut, nem toboroz

  A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLL

  NCT03336333· 3. fázis· Forrás

• Fut, nem toboroz

  Adjuvant Low Dose Aspirin in Colorectal Cancer

  NCT02647099· 3. fázis· Forrás

• Fut, nem toboroz

  CINC424A2X01B Rollover Protocol

  NCT02386800· 4. fázis· Forrás

Egyszerre toboroz

Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.

• Krónikus vesebetegség1 toboroz
• Méhnyakrák1 toboroz
• Mielóma multiplex1 toboroz
• Pitvarfibrilláció1 toboroz
• Vastagbélrák1 toboroz

Kutatók

Ide még nem kötődik kutató.

Lezárt vizsgálatok

• Lezárult

  Acalabrutinib Safety Study in Untreated and Relapsed or Refractory Chronic Lymphocytic Leukemia Patients

  NCT04008706· 3. fázis· Forrás

• Lezárult

  SGLT2 Inhibitor or Metformin as Standard Treatment of Early Stage Type 2 Diabetes

  NCT03982381· 4. fázis· Forrás

• Fut, nem toboroz

  A Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

  NCT03462719· 3. fázis· Forrás

• Lezárult

  autologous Transplantation after a Rituximab/Ibrutinib/Ara-c containing iNduction in Generalized mantle cell Lymphoma – a randomized European MCL Network trial

  2024-511235-10-00· 3. fázis· Forrás